Aileron Therapeutics, Inc. (ALRN)
NASDAQ: ALRN · Real-Time Price · USD
4.120
+0.270 (7.01%)
At close: Oct 31, 2024, 4:00 PM
3.990
-0.130 (-3.16%)
After-hours: Oct 31, 2024, 6:46 PM EDT

Company Description

Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States.

The company’s lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).

Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion.

The company’s pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications.

The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007.

Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.

Aileron Therapeutics, Inc.
Aileron Therapeutics logo
Country United States
Founded 2001
IPO Date Jun 29, 2017
Industry Biotechnology
Sector Healthcare
Employees 15
CEO James Windsor

Contact Details

Address:
12407 N. Mopac Expy., Suite 250 #390
Austin, Texas 78758
United States
Phone 737 802 1989
Website aileronrx.com

Stock Details

Ticker Symbol ALRN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001420565
CUSIP Number 00887A105
ISIN Number US00887A2042
Employer ID 13-4196017
SIC Code 2834

Key Executives

Name Position
Dr. James Brian Windsor Ph.D. Chief Executive Officer, President and Director
Timothy M. Cunningham CPA, M.B.A. Interim Chief Financial Officer and Principal Accounting Officer

Latest SEC Filings

Date Type Title
Aug 21, 2024 8-K Current Report
Aug 14, 2024 8-K Current Report
Aug 14, 2024 10-Q Quarterly Report
Jul 26, 2024 8-K Current Report
Jul 26, 2024 424B5 Filing
Jul 26, 2024 424B5 Filing
Jul 9, 2024 ARS Filing
Jul 9, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Jul 9, 2024 DEF 14A Other definitive proxy statements
Jun 5, 2024 8-K Current Report